Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVSNYSEARCA:XLV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVSNovartis$112.37+1.4%$108.65$92.35▼$120.92$229.68B0.561.51 million shs2.93 million shsXLVHealth Care Select Sector SPDR Fund$143.13-0.8%$146.51$135.95▼$159.64$37.80B0.717.52 million shs10.90 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVSNovartis+1.20%+0.66%+0.03%+14.07%+17.37%XLVHealth Care Select Sector SPDR Fund+0.67%-0.30%-3.53%+4.86%+0.08%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNVSNovartis2.2815 of 5 stars0.95.02.50.03.90.01.9XLVHealth Care Select Sector SPDR FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVSNovartis 1.80Reduce$123.389.79% UpsideXLVHealth Care Select Sector SPDR Fund 2.77Moderate Buy$143.13N/ACurrent Analyst Ratings BreakdownLatest NVS and XLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/13/2025NVSNovartisUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/12/2025NVSNovartisMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderweight2/4/2025NVSNovartisDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy2/3/2025NVSNovartisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVSNovartis$51.72B4.44$11.20 per share10.03$21.59 per share5.20XLVHealth Care Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVSNovartis$11.94B$5.8819.1112.751.7023.56%37.24%15.85%4/22/2025 (Estimated)XLVHealth Care Select Sector SPDR FundN/AN/A29.15∞N/AN/AN/AN/AN/ALatest NVS and XLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/22/2025N/ANVSNovartis$2.07N/AN/AN/A$12.92 billionN/A1/31/2025Q4 2024NVSNovartis$1.80$1.98+$0.18$1.41$12.86 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVSNovartis$2.512.23%+5.34%42.69%N/AXLVHealth Care Select Sector SPDR Fund$2.341.63%N/AN/AN/ALatest NVS and XLV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/9/2025XLVHealth Care Select Sector SPDR Fund$0.56453/24/20253/24/20253/26/20251/9/2025XLVHealth Care Select Sector SPDR Fund$0.56453/24/20253/24/20253/26/20252/20/2025NVSNovartis$3.86953/12/20253/12/20253/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVSNovartis0.481.040.84XLVHealth Care Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVSNovartis13.12%XLVHealth Care Select Sector SPDR FundN/AInsider OwnershipCompanyInsider OwnershipNVSNovartis0.01%XLVHealth Care Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVSNovartis101,7002.04 billion2.04 billionOptionableXLVHealth Care Select Sector SPDR FundN/A264.07 millionN/ANot OptionableNVS and XLV HeadlinesRecent News About These CompaniesConsumer staples Q1 roundup: Philip Morris tops chart, Target worse performerApril 2 at 7:47 AM | msn.comSolventum Stock: Is SOLV Outperforming the Healthcare Sector?April 2 at 7:47 AM | msn.comBe Smart This April Fool's Day: Buy Market-Beating ETFs of Q1April 1 at 11:00 AM | zacks.comWaters Corporation Stock: Is WAT Outperforming the Healthcare Sector?March 26, 2025 | msn.comHealth Care Select Sector SPDR Fund (NYSEARCA:XLV) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?March 26, 2025 | americanbankingnews.comS&P sector rankings as the first quarter of 2025's close is around the cornerMarch 24, 2025 | msn.com3 Sector ETFs & Stocks to Gain Despite Downbeat February Jobs DataMarch 14, 2025 | zacks.comMerck and 8 More Healthcare Stocks for Nervous Dividend InvestorsMarch 13, 2025 | msn.comSelect Sector SPDR ETFs: Strategic Investment with Sector-Specific AllocationsMarch 12, 2025 | finance.yahoo.comRecession Fears Looming? Secure Your Portfolio With These ETFsMarch 11, 2025 | zacks.comHealth Care Sector Trying to Bounce BackMarch 6, 2025 | theglobeandmail.comShifting Tides in Leadership: Markets Play DefenseMarch 6, 2025 | etftrends.comTime for Defensive Sector ETFs?February 27, 2025 | zacks.comHealthcare best performing sector as market angst buildsFebruary 25, 2025 | marketwatch.comHealthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.February 25, 2025 | msn.comHealth Care Has Been a Top SectorFebruary 22, 2025 | finance.yahoo.comWhat Top-Performing Healthcare Funds Are Buying NowFebruary 19, 2025 | msn.comFinal Trade: FWONK, XLV, MSFT, PEPFebruary 13, 2025 | youtube.com18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecardFebruary 8, 2025 | msn.comFinancials, Health Care Sectors Leading U.S. Stocks Higher In 2025February 7, 2025 | seekingalpha.comS&P 500 Earnings Set to Shine: January's Critical Market Test (XLV)December 27, 2024 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVS and XLV Company DescriptionsNovartis NYSE:NVS$112.37 +1.60 (+1.44%) Closing price 03:59 PM EasternExtended Trading$111.70 -0.67 (-0.60%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Health Care Select Sector SPDR Fund NYSEARCA:XLV$143.13 -1.17 (-0.81%) Closing price 04:10 PM EasternExtended Trading$142.72 -0.41 (-0.29%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
